Southern Finance and Economics, November 2nd - Novo Nordisk announced on its official website on Friday (November 1st) the results of the first phase of an ongoing Phase III trial, in which 2.4 milligrams of semaglutide showed significant improvements in liver fibrosis and MASH resolution. Novo Nordisk's "ESSENSE" is a key phase III, 240 week double-blind trial involving 1200 adults with MASH and moderate to advanced liver fibrosis. The participants were divided into a 2.4mg semaglutide group and a placebo group in a 2:1 ratio based on standard treatment. The primary endpoint of the experiment was achieved: at week 72, 37.0% of patients in the semaglutide group showed improvement in liver fibrosis without worsening of steatohepatitis, compared to 22.5% in the placebo group; 62.9% of patients in the semaglutide group experienced relief of steatohepatitis without worsening of liver fibrosis, compared to 34.1% in the placebo group.